Apimeds Pharmaceuticals US, Inc.
APUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001894525
No open-market purchases or sales by Apimeds Pharmaceuticals US, Inc. insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $383.7K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Apimeds Pharmaceuticals US, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 6 | 7 | +1 |
| Shares | 448.8K | 426.3K | −22.5K (−5.0%) |
| Value | $803.0K | $383.7K | −$419.3K (−52.2%) |
New holders (2)
Institutions that held Apimeds Pharmaceuticals US, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 15,993 | $14.4K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,664 | $1.50K | 0.00% |
Sold out (1)
Institutions that held Apimeds Pharmaceuticals US, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Two Sigma Securities, LLC | 10,550 | $18.9K |